Vasopressin Side Effects: Safety Signals and Warnings
Vasopressin safety concerns are compound-specific. The main listed side effects are Hyponatremia (with excessive doses), Peripheral vasoconstriction and digital ischemia, and Abdominal cramping. The main warning signals are Water intoxication/hyponatremia risk with excessive doses, Digital and mesenteric ischemia - monitor extremities, and Cardiac ischemia risk - use with caution in coronary artery disease.
Direct Answer
Vasopressin (Vasostrict) is FDA-approved for vasodilatory shock (septic shock, post-cardiotomy vasodilatory shock) with Phase 3 evidence from the VASST trial showing non-inferiority to norepinephrine and steroid-sparing potential in septic shock. As an endogenous hormone with a distinct vasoconstrictive mechanism, it is a standard vasopressor in critical care medicine.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Vasodilatory shock, septic shock vasopressor therapy, V1a/V2 receptor pharmacology research
Reported Side Effects
- Hyponatremia (with excessive doses)
- Peripheral vasoconstriction and digital ischemia
- Abdominal cramping
- Nausea
- Chest pain
- Arrhythmias
Warnings
- Water intoxication/hyponatremia risk with excessive doses
- Digital and mesenteric ischemia - monitor extremities
- Cardiac ischemia risk - use with caution in coronary artery disease
- Extravasation can cause tissue necrosis
- Can cause uterine contractions - use caution in pregnancy
Known or Plausible Interactions
- Catecholamine vasopressors (additive vasoconstrictive effect)
- Carbamazepine and chlorpropamide (potentiate antidiuretic effect)
- Lithium and demeclocycline (antagonize antidiuretic effect)
- Ganglionic blocking agents (enhanced vasopressor response)
Regulatory Context
FDA-approved for vasodilatory shock (Vasostrict), diabetes insipidus, and prevention/treatment of postoperative abdominal distension. Available by prescription. Multiple manufacturers.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Vasodilatory Shock Treatment (Level A), Diabetes Insipidus Management (Level A), and Cardiac Arrest Adjunct (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Vasopressin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/vasopressin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.